properdin
complement
amlitelimab
intetumumab
zanolimumab
seroimmunity
antiserum
immunome
active immunity
antiantibody
MYD88
immunoexpression
glembatumumab
immunoprotein
alloantibody
cytokine
presentation
human gamma globulin
gamma globulin
namilumab
antihuman
elotuzumab
tucotuzumab
soravtansine
sonepcizumab
antigenomic
bivatuzumab
immunosubunit
ipilimumab
immunodeposition
carlumab
monospecific
affinity
immunodeposit
hematoimmune
agonistic monoclonal antibody
sifalimumab
-lim-
talizumab
secukinumab
immunoexpress
ocrelizumab
bursopentine
immunocompetence
pathoantigen
muromonab
intrabody
hyperimmunoglobulin
complementology
immunoarchitecture
vobarilizumab
immunoprecipitant
immunogen
allotype
immunoadaptor
mavrilimumab
affibody
immunoproteomics
-ab
ruplizumab
immunopeptide
immunology
gimsilumab
vepalimomab
immunoprecipitate
immune privilege
IgD
immunoglobulin D
immunoresponsive
immunosystem
adjuvant
-zumab
paratope
envoplakin
immunoantigen
olendalizumab
auto-immune
recognition
immunoreactant
immunoserum
tisotumab
immunocytic
immunohistopathology
antisubstance
seroconversion
microantibody
onartuzumab
immunoglobin
sirukumab
immunoblotting
antigenic
otilimab
faralimomab
immunocompetent
reagin
bispecific
histocompatibility antigen